Argenx Just Landed Another Phase 3 Win — and Wall Street May Be Missing the Bigger Story
Argenx (ARGX +0.83%) already markets Vyvgart Hytrulo for treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), two rare chronic autoimmune diseases. It appears to be on track to add another approved indication for the drug. On Aug. 17, 2026, Argenx announced positive results from a Phase 3 clinical study evaluating Vyvgart Hytrulo…